CAMELLIA-TIMI

  • STATUS
    Recruiting
Updated on 23 November 2020

Summary

CAMELLIA-TIMI

Description

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaluate the effect of long-term treatment with BELVIQ (Lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to Type 2 Diabetes Mellitus in obese and overweight subjects with Cardiovascular Disease or Multiple Cardiovascular risk factors

IRB Number: 014-016

Legacy Heart Center

6601 Preston Road

Plano, TX 75024

Lead Principal Investigator: Marcus McKenzie, MD

Details
Clinical Study IdentifierTX138930
Last Modified on23 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Gender: Male or Female
BMI greater than or equal to 27 kg/m^2
Subjects able and willing to comply with a reduced-calorie diet and an increased physical activity program
Age greater than or equal to 40 years with established CV disease as defined by one of the following
History of documented MI or ischemic stroke
History of peripheral artery disease
History of revascularization (coronary, carotid, or peripheral artery)
Significant unrevascularized coronary arterial stenosis OR age greater than or equal to 55 years for women or greater than or equal to 50 years for men who have Type 2 Diabetes Mellitus without established CV disease plus at least one of the following CV risk factors
Hypertension, or currently receiving therapy for documented hypertension
Dyslipidemia, or currently taking prescription lipid-lowering therapy for documented dyslipidemia

Exclusion Criteria

Moderate or greater symptoms of congestive cardiac failure (New York Heart Association [NYHA] class III or IV)
Moderate renal impairment, severe renal impairment, or end stage renal disease (ESRD)
Severe hepatic impairment
Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations
History or evidence of clinically significant disease (e.g., malignancy, cardiac, respiratory, gastrointestinal, renal or psychiatric disease)
Use of lorcaserin HCl prior to Screening or hypersensitivity to lorcaserin HCl or any of the excipients
Planned bariatric surgery
Females must not be breastfeeding or pregnant
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet